Introduction
============

Many complex medical disorders managed in the intensive care unit (ICU) are associated with an elevation of pulmonary arterial pressure (PAP). Usually this is transient, of mild to moderate severity and not considered to affect patient outcome. However, in some circumstances serious and prolonged elevation of PAP progresses to severe acute pulmonary hypertension, leading to life threatening complications including refractory systemic arterial hypotension, severe hypoxemia, right ventricular (RV) dysfunction and failure and ultimately resulting in cardiogenic and/or obstructive shock and death. Unfortunately, in most cases acute pulmonary hypertension remains under diagnosed and its treatment begins only after serious complications have developed.

It is well known that left ventricular dysfunction/failure is one of the main causes of pulmonary venous hypertension, particularly in the cardiac ICU setting ([@b86-vhrm-4-1043]). However, this review is focused on the pathophysiology, monitoring and management of the acute and acute on chronic arterial pulmonary hypertension treated in the noncardiac ICU.

Definition of arterial pulmonary hypertension
=============================================

Pulmonary hypertension is characterized by elevated PAP and secondary RV failure. The currently accepted clinical classification of pulmonary hypertension (World Health Organization \[WHO\] Venice 2003) distinguishes five main types of the condition ([Table 1](#t1-vhrm-4-1043){ref-type="table"}) ([@b38-vhrm-4-1043]). However, this classification of sustained (chronic) pulmonary hypertension is less applicable in acute settings. In order to clarify the terminology of acute pulmonary hypertension and distinguish it from chronic pulmonary hypertension, we provide a classification of acute pulmonary hypertension according to underlying pathophysiologic mechanisms, clinical features, natural history, and response to treatment ([Table 2](#t2-vhrm-4-1043){ref-type="table"}).

Chronic pulmonary arterial hypertension (PAH) is defined by a mean pulmonary arterial pressure (PAP) \>25 mmHg at rest or \>30 mmHg with exercise, associated with a pulmonary capillary wedge pressure (PCWP) \<15 mmHg and pulmonary vascular resistance (PVR) \>3 mmHg/l/min (Wood units) measured by right heart catheterization. It is considered to be severe if mean PAP \>45 mm Hg; of moderate severity, if mean PAP 35--45 mm Hg or mild, if mean PAP \<35 mm Hg. Despite clinical and pathophysiologic differences among different kinds of pulmonary hypertension, it is widely accepted to apply mean PAP definitions developed for PAH to other types of pulmonary hypertension.

Cor pulmonale is the most important consequence of pulmonary hypertension and remains a frequent cause of RV failure and death in patients with arterial pulmonary hypertension in the ICU. Cor pulmonale is defined as a change in structure and function of the RV, which develops as a result of a respiratory disorder or other abnormalities in the pulmonary circulation system. Almost all diseases manifested by arterial pulmonary hypertension can cause cor pulmonale: either as an acute condition, if the arterial pulmonary hypertension develops acutely (as with sepsis/acute lung injury \[ALI\], pulmonary embolism \[PE\], cardiac surgery, drug-induced, etc), or as a chronic condition, if arterial pulmonary hypertension is mainly chronic (as in chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), sleep disorder breathing, chronic hypoventilation, PAH, chronic thromboembolic pulmonary hypertension/CTEPH, portopulmonary hypertension etc). Increased RV afterload leads to RV dilatation in most acute cases of cor pulmonale when there is not enough time for adaptive mechanisms (eg, RV hypertrophy) to develop. Thus, RV dilatation or RV hypertrophy are the main features of the acute and chronic cor pulmonale, respectively.

Pathophysiology of pulmonary hypertension
=========================================

Pathological changes in each segment of the pulmonary vasculature (precapillary arteries and arterioles, capillary beds, and postcapillary pulmonary veins and venules). can lead to the development of pulmonary hypertension. Pulmonary venous and capillary hypertension typically results from left ventricular (LV) diastolic dysfunction, valvular heart disease, or rarely, pulmonary venous disorders. The mechanisms of arterial pulmonary hypertension include vascular thromboembolism, endothelial dysfunction, (hypoxic) vasoconstriction, pulmonary vascular remodeling, smooth muscle proliferation with or without neointimal formation and *in situ* thrombosis ([@b52-vhrm-4-1043]). Endothelial dysfunction with an imbalance between vasodilation and vasoconstriction, and between apoptosis and proliferation is thought to play a pivotal role in the development of chronic progressive PAH. Hypoxemic pulmonary vasoconstriction is an important determinant of arterial pulmonary hypertension in patients with respiratory disorders ([@b52-vhrm-4-1043]). In many types of pulmonary hypertension production of endogenous vasodilators (nitric oxide \[NO\] and prostacyclin) is impaired and production of vasoconstrictors (endothelin-1) is increased ([@b52-vhrm-4-1043]). This forms the pathophysiologic basis of common treatment strategies for arterial pulmonary hypertension which attempt to achieve balance in key molecular pathways by increasing available NO and prostacyclin, or reducing the effects of endothelin-1.

Acute arterial pulmonary hypertension is characterized by a sudden increase in PAP. Mechanical obstruction with subsequent vasoconstriction characterizes acute pulmonary hypertension in PE. In ALI/acute respiratory distress syndrome (ARDS), both hypoxic pulmonary vasoconstriction and accumulation of intravascular fibrin and cellular debris contribute to subsequent vascular obliteration and pulmonary hypertension ([@b97-vhrm-4-1043]). Endotoxin plays a significant role in the development of pulmonary hypertension during sepsis. Multiple animal studies have shown that endotoxin can cause not only systemic hypotension, but also pulmonary biphasic hypertension, along with a decrease in compliance and an increase in resistance of respiratory system ([@b2-vhrm-4-1043]). Endotoxin-dependent hemodynamic and respiratory effects are mediated by excessive release of inflammatory mediators and imbalances in production of NO, prostanoids, and endothelin-1 (ET-1) ([@b142-vhrm-4-1043]; [@b2-vhrm-4-1043]). Pulmonary hypertension in endotoxemia is characterized by constriction of proximal pulmonary arteries during the early phase followed by decreased compliance of the distal pulmonary vasculature ([@b71-vhrm-4-1043]). Endotoxin infusion can dramatically affect RV function: in the very early phase of endotoximic shock, RV-vascular coupling is preserved by an increase in RV contractility. Later, myocardial oxygen consumption and energy cost of RV contractility are increased, which along with progressive endotoxin-induced pulmonary hypertension lead to RV dysfunction and failure ([@b72-vhrm-4-1043]). Maintenance of appropriate coronary perfusion is therefore an important therapeutic consideration during septic shock.

Neurohormonal activation is an important factor in both acute and chronic RV failure. The consequence of sympathetic hyperactivity is an increase in pulmonary vascular resistance (PVR) with impedance of flow, causing RV strain that impairs filling and causes RV volume and pressure overload. The RV dilates (and eventually hypertrophy can develop in chronic gradual pulmonary hypertension), encroaching on the LV and decreasing preload, cardiac output, and coronary perfusion. Increased RV wall stress results in RV ischemia ([@b135-vhrm-4-1043]). Tricuspid regurgitation develops as a result of RV dysfunction and portends a poor prognosis ([@b103-vhrm-4-1043]). RV systolic dysfunction, severe tricuspid regurgitation, arrhythmias, and LV dysfunction caused by ventricular interdependence may contribute to low cardiac output and hypotension in patients with pulmonary hypertension. Regardless of the underlying cause of pulmonary hypertension, the final common pathway for hemodynamic deterioration and death is cor pulmonale and RV failure. Among other clinically important adverse effects of right heart failure is the development of systemic venous hypertension leading to concomitant visceral organ congestion and dysfunction.

It is important to emphasize the difference between the ability of RV to adapt to sudden (acute) vs gradual (chronic) elevation of PAP. The normal RV can acutely adapt to high flow, but is not able to tolerate any but very short acute high pressure load ([@b14-vhrm-4-1043]). The normal RV cannot acutely increase and sustain mean PAP \> 40 mm Hg for more than a brief period of time ([@b24-vhrm-4-1043]).

Common causes of arterial pulmonary hypertension in noncardiac ICU
==================================================================

Acute on chronic arterial pulmonary hypertension
------------------------------------------------

Patients with preexisting pulmonary hypertension (ie, acute on chronic arterial pulmonary hypertension) are particularly vulnerable to acute illnesses, which commonly result in rapid deterioration and even death ([@b49-vhrm-4-1043]). Besides PAH several other conditions are associated with chronic arterial pulmonary hypertension including interstitial lung diseases, COPD, chronic hypoventilation and sleep disorder breathing, portopulmonary hypertension and chronic pulmonary thromboembolism. Multiple predisposing factors ([Table 3](#t3-vhrm-4-1043){ref-type="table"}) can precipitate acute on chronic pulmonary hypertension and cor pulmonale and lead to adverse outcome in patients with preexisting chronic arterial pulmonary hypertension.

Patients with chronic pulmonary arterial hypertension can rapidly deteriorate and usually die from progressive RV failure (49%), progressive respiratory failure (18%), or sudden cardiac death (17%). Cardiopulmonary resuscitation (CPR), even when attempted in the hospital setting is rarely successful. Only 6% patients survived for more than 90 days and most survivors had identifiable causes of circulatory arrest that were rapidly reversible. The pulmonary blood flow is virtually absent in these patients during CPR ([@b49-vhrm-4-1043]). Interestingly, hemodynamic measurements obtained within 3 month before CPR did not reveal any significant differences between the survivors and non survivors. In 54%, cardiorespiratory arrest was associated with an intercurrent illness ([@b49-vhrm-4-1043]), illustrating how preexisting pulmonary hypertension adversely affects patients' compensatory capacity and ability to survive an acute illness.

Acute arterial pulmonary hypertension
-------------------------------------

Massive PE, sepsis, and ALI are the main causes of acute arterial pulmonary hypertension in the adult patient population ([@b139-vhrm-4-1043]).

### Massive pulmonary embolism

Massive PE involving at least two lobar arteries is the most important cause of acute cor pulmonale developing in 61% of patients with massive PE. The mortality ranges from 3% in hemodynamically stable patients to 59% in unstable patients ([@b61-vhrm-4-1043]; [@b137-vhrm-4-1043]).

Hemodynamic instability in a setting of PE is defined as systolic blood pressure (SBP) \<90 mmHg or a drop in SBP \>40 mmHg from baseline for more then 15 minutes, which is not otherwise explained by hypovolemia, sepsis, or new arrhythmia ([@b61-vhrm-4-1043]) The degree of shock inferred from the presence of metabolic acidosis, but not TTE (TransThoracic ECHO) findings is the most powerful predictor of death in these patients ([@b137-vhrm-4-1043], [@b138-vhrm-4-1043]).

### Acute respiratory distress syndrome and sepsis

The onset of acute cor pulmonale as a complication of ALI and its more severe form, ARDS, is more gradual than in patients with massive PE. It usually occurs at least 48 hours after the beginning of respiratory support ([@b139-vhrm-4-1043]).

Evaluation of RV function by TEE (TransEsophageal ECHO) in a group of 75 ARDS patients submitted to protective ventilation demonstrated 25% incidence of acute RV dysfunction, with detrimental hemodynamic consequences associated with tachycardia. However, those changes in heart function were reversible in patients who recovered and did not increase mortality ([@b139-vhrm-4-1043]). Although the initial magnitude of pulmonary hypertension was not an indicator of mortality, PAP further increased in nonsurvivors, but not in survivors when followed for 7 days ([@b75-vhrm-4-1043]). Thus, development of the pulmonary hypertension in ARDS patients seems to be a sign of poor prognosis. In a cohort of 352 ARDS patients both mortality rate and incidence of cor pulmonale were related to the level of plateau pressure during mechanical ventilation. An interaction between plateau pressure and cor pulmonale was observed whereas odds ratio of dying for an increase in plateau pressure (from 18--26 to 27--35 cm H~2~O) in patients without cor pulmonale was 1.05 (p= 0.635), in contrast to odds ratio of 3.32 (p \< 0.034) in patients with cor pulmonale ([@b56-vhrm-4-1043]). The implementation of low tidal volume ventilation in patients with ARDS has significantly lowered not only mortality (down to 32%), but also incidence of acute cor pulmonale in this patient population ([@b139-vhrm-4-1043]).

In addition to being the major risk factor for ARDS development, sepsis itself can sometimes lead to severe acute arterial pulmonary hypertension ([@b120-vhrm-4-1043]).

### Intra- and post-surgical pulmonary hypertension

Some surgical interventions, in particular vascular, cardiac and thoracic surgery may cause acute elevation of PAP either during the surgery or shortly after the intervention has been completed. This is particularly dangerous in patients with preexisting pulmonary hypertension, since even short periods of RV pressure overload can lead to profound decompensation with all negative hemodynamic consequences. Preexisting pulmonary hypertension is one of the major risk factors for morbidity and mortality in cardiothoracic surgery patients ([@b12-vhrm-4-1043]). Pulmonary hypertension is a major determinant of perioperative morbidity and mortality in special situations such as heart and lung transplantation, pneumonectomy, and ventricular assist device placement ([@b125-vhrm-4-1043]).

Airway manipulations and some induction agents can precipitate an acute increase in PVR ([@b47-vhrm-4-1043]; [@b50-vhrm-4-1043]). At the same time sedative/anesthetic drugs can decrease ventricular contractility (eg, barbiturates, propofol) or decrease SVR (eg, propofol) negatively affecting systemic and coronary perfusion pressure. All this can cause severe circulatory collapse, particularly in patients with preexisting pulmonary hypertension ([@b50-vhrm-4-1043]). It is believed that an elevated PAP during and after surgery develops secondary to acute left heart failure/dysfunction or can be a consequence of pulmonary parenchymal and endothelial injury with activation of the systemic and pulmonary inflammatory response to cardiopulmonary bypass circulation and/or ischemia-reperfusion ([@b143-vhrm-4-1043]). Protamine-mediated acute pulmonary hypertension and RV failure in the perioperative period are common (1.78%) complications of cardiopulmonary bypass circulation during open-heart operations ([@b107-vhrm-4-1043]).

Pulmonary hypertension can also develop later as a result of ARDS ([@b94-vhrm-4-1043]) or other complications (sepsis, PE, etc) not directly related to either surgery or anesthesia.

Diagnosis and monitoring of patients with pulmonary hypertension in ICU
=======================================================================

A high level of suspicion is the key point in establishing a timely diagnosis of acute arterial pulmonary hypertension. Clinical presentation, physical exam, electrocardiogram and chest radiography can suggest pulmonary circulation abnormality. However, those data are not specific enough to be useful in diagnosing acute pulmonary hypertension in ICU. Pulmonary hypertension is usually recognized when the patient develops obvious signs of progressive RV failure, and during hemodynamic monitoring by echocardiogram or a pulmonary artery catheterization. In many cases pulmonary hypertension remains undiagnosed and its treatment begins only after serious complications have developed. Timely assessment of pulmonary artery pressures, cardiac output (CO) and pulmonary vascular resistance with the help of pulmonary artery catheterization and/or echocardiography is crucial for optimal management of patients with pulmonary hypertension. The role of alternative diagnostic tests such as volumetric capnography is unclear at present ([@b98-vhrm-4-1043]).

Pulmonary artery catheterization
--------------------------------

Pulmonary artery (PA) catheterization is considered a gold standard for the diagnosis of pulmonary hypertension ([@b22-vhrm-4-1043]) when chronic pulmonary hypertension is suspected. Besides direct measurement of the pulmonary hemodynamic parameters it also provides useful information regarding response to vasodilator therapy. Analysis of mixed venous oxygen saturations during passage of the PA catheter on its way through the cardiac chambers can allow diagnosis of intracardiac shunts. A pulmonary capillary wedge pressure (PCWP) measurement reflects left ventricular end-diastolic (filling) pressure. Values \<15 mm Hg rule out left ventricular, valvular and pulmonary venous diseases as possible causes of the pulmonary hypertension ([@b22-vhrm-4-1043]).

In critical care settings PA catheterization and monitoring is highly desirable in patients with severe pulmonary hypertension and in patients with progressive heart failure ([@b34-vhrm-4-1043]). It is important to emphasize that the thresholds required for diagnosis of severe chronic pulmonary hypertension are incompatible with life in patients with acute pulmonary hypertension and usually reflect worsening of preexisting chronic pulmonary hypertension. Although there is a little doubt that hemodynamic data are valuable in the care of critically ill patients with acute conditions complicated by pulmonary hypertension, there is no data available on how PA monitoring could affect management and outcome of these patients. Indeed, placing a PA catheter could be a challenging and dangerous procedure in such patient population. Technical difficulties could be related to severe tricuspid regurgitation, RV dilatation, elevated PAP, and decreased cardiac output. Complications of PA catheterization are particularly dangerous in patients with pulmonary hypertension and RV dysfunction/failure. Arrhythmias in response to PA catheterization can have potentially life-threatening consequences by decreasing cardiac output, or induction of fatal ventricular arrhythmias. Obtaining a PCWP may be technically difficult in patients with markedly elevated PAP, and also carries a high risk of sometimes fatal pulmonary arterial rupture. Finally, the presence of tricuspid regurgitation can significantly decrease the accuracy of cardiac output calculations by thermodilution. Theoretically, Fick's method could be more accurate, but in critically ill patients with increased pulmonary metabolism and high or very low cardiac output its accuracy may not be optimal ([@b21-vhrm-4-1043]).

Echocardiography
----------------

Echocardiography has become an important tool not only for screening of chronic pulmonary hypertension, but also for diagnosing and determining the degree and clinical significance of pulmonary hypertension in critically ill patients ([@b49-vhrm-4-1043]; [@b52-vhrm-4-1043]). It can noninvasively visualize cardiac anatomy and certain intracardiac shunts and valvular abnormalities, estimate right atrial and PAP, determine the severity of right and left ventricular dysfunction, wall motion abnormalities and reveal other potential causes of pulmonary hypertension. In the absence of pulmonary outflow obstruction, pulmonary artery systolic pressure is equivalent to right ventricular systolic pressure (RVSP), which can be calculated from measured systolic regurgitant tricuspid flow velocity and estimated right atrial pressure. Pulmonary hypertension is usually defined as RVSP \>35 mm Hg with the expected upper normal limit up to 40 mm Hg in older or obese subjects ([@b87-vhrm-4-1043]). Among 3790 healthy people who underwent echocardiography RVSP was highly variable in the range of 15--57 mmHg and was associated with age, body mass index (BMI), gender, wall thickness, and ejection fraction. A RVSP \>40 mm Hg was found in 6% of those \>50 years old and 5% of those with a BMI \>30 kg/m^2^ ([@b87-vhrm-4-1043]). Therefore, not every elevation of RVSP indicates a presence a pathological condition. Possible explanations for mildly elevated RVSP detected by echo-cardiography include ([@b9-vhrm-4-1043]): 1) overestimation of the RVSP in a patient with true normal pulmonary pressure; 2) serendipitous observation of a transient pressure elevation in an otherwise healthy individual; 3) discovery of stable mild pulmonary hypertension; or 4) discovery of early progressive PAH.

Echocardiographic signs of significant pulmonary hypertension include RV dilation (D-shaped right ventricle) and its hypertrophy (in sustained cases), septal dyskinesia and bowing into the LV during late systole to early diastole, RV hypokinesis, tricuspid regurgitation, right atrial enlargement, and a dilated inferior vena cava ([@b22-vhrm-4-1043]; [@b138-vhrm-4-1043]; [@b15-vhrm-4-1043]). In patients with chronic PAH predictors of poor outcome include right atrial enlargement, septal bowing, and the development of a pericardial effusion ([@b111-vhrm-4-1043]).

Increased RV size combined with increased outflow resistance and reduced ejection fraction have been also described in acute cor pulmonale ([@b138-vhrm-4-1043]). A specific pattern of RV dysfunction in acute pulmonary embolism has been characterized by a severe hypokinesia of the RV mid-free wall, with normal contractions of the apical segment ([@b82-vhrm-4-1043]).

TTE results were poorly predictive of the risk of death in patients who developed acute cor pulmonale ([@b72-vhrm-4-1043]). However, definition of the acute cor pulmonale as right ventricular end-diastolic area/left ventricular end-diastolic area (RVEDA/LVEDA) ratio in the long axis greater than 0.6 associated with septal dyskinesia in the short axis could be used to stratify the severity of the condition ([@b137-vhrm-4-1043]; [@b30-vhrm-4-1043]).

Images may be suboptimal in critically ill patients because of limitations related to patient's general condition, limited positioning, attached monitoring devices, wound dressings, or ventilatory support. TEE may be more accurate and sensitive in critically ill patients than TTE, especially in acute diseases such as pulmonary embolism when acute pulmonary hypertension is highly suspected ([@b60-vhrm-4-1043]). Newly developed handheld ultrasound devices capable of TEE may sufficiently replace a standard cart-based TEE system in unstable critically ill patients ([@b118-vhrm-4-1043]).

Advanced Doppler ECHO techniques allow for comprehensive hemodynamic assessment of the patients with pulmonary hypertension. A high correlation between PA catheter and Doppler echocardiography evaluations of cardiac output, transpulmonary gradient and PVR were observed in patients with severe pulmonary hypertension ([@b119-vhrm-4-1043]).

Troponin
--------

Serum troponin may be elevated in patients with pulmonary hypertension and has been associated with RV overdisten-sion and/or ischemia. Troponin I leak due to acute right ventricular strain from pulmonary embolism has been well studied, and may predict mortality ([@b90-vhrm-4-1043]; [@b69-vhrm-4-1043]).

Natriuratic peptides
--------------------

Elevated BNP is an important prognostic indicator and correlates strongly with PVR, cardiac output, and functional status in patients with PAH ([@b78-vhrm-4-1043]). A high level of plasma BNP, and in particular, a further increase in plasma BNP during follow-up, may have a strong, independent association with increased mortality rates in this patient population ([@b101-vhrm-4-1043]). However, the significance of measuring BNP level in patients with pulmonary hypertension in the acute setting remains unclear.

Management of arterial pulmonary hypertension in noncardiac ICU
===============================================================

General management principles
-----------------------------

### Acute on chronic pulmonary hypertension

Patients with chronic pulmonary hypertension usually have multiple predisposing factors ([Table 3](#t3-vhrm-4-1043){ref-type="table"}), which make them more vulnerable to acute conditions and explain decreased ability to survive acute illness ([@b49-vhrm-4-1043]). Tighter monitoring combined with early diagnosis and appropriate intervention increases the chance of survival. Treatment strategies for such patients should be generally directed at rapid reversal of the precipitating condition as well as at relieving RV pressure overload and maintaining systemic pressure for coronary and end organ perfusion. Unlike patients with acute pulmonary hypertension ([@b24-vhrm-4-1043]), patients who develop acute pulmonary hypertension on top of preexisting pulmonary hypertension can generate higher pulmonary arterial pressure and also require higher RV preload (because of RV hypertrophy).

### Massive pulmonary embolism

Therapy for acute massive pulmonary embolism with associated hemodynamic instability or cardiogenic/obstructive shock aims at urgently relieving mechanical obstruction of the pulmonary circulation by either pharmacologic thrombolysis or by surgical or catheter thrombectomy (or mechanical clot disruption) ([@b18-vhrm-4-1043]; [@b145-vhrm-4-1043]). Patients with massive PE but without hemodynamic instability are less likely to benefit from thrombolytic therapy. The time the resolution of RV dilatation, which usually takes between 10 and 20 days, is hastened by thrombolytic therapy ([@b137-vhrm-4-1043]).

### Pulmonary hypertension associated with ARDS and sepsis

The therapy of acute pulmonary hypertension in patients with sepsis and ARDS is generally aimed at optimizing gas exchange and minimizing ventilator induced lung injury. Inhaled pulmonary vasodilators are sometimes used in order to prevent or relieve acute cor pulmonale.

Pulmonary vasodilators
----------------------

Ability to produce sustained pulmonary vasodilation is not the only factor affecting the decision to choose particular vasodilator in treatment of acute pulmonary hypertension. Route of administration, half-life and systemic effects should also be considered. Vasodilators administered intravenously may decrease PVR, but they also have longer half lives and affect systemic circulation. A decrease in systemic mean arterial pressure may result in reduced right coronary blood flow and further deterioration of RV performance. Inhalation of pulmonary vasodilators can improve ventilation/perfusion (V/Q) matching by reaching and subsequently vasodilating only well ventilated areas of the lung. Inhaled pulmonary vasodilators with a short half-life and no systemic vasodila-tion effect are considered a treatment of choice for acute arterial pulmonary hypertension.

### Inhaled NO

Inhaled NO (INO) is a potent vasodilator that dilates pulmonary vasculature in ventilated lung areas, thereby improving V/Q match and oxygenation, and reducing PAP ([@b109-vhrm-4-1043]) and RV oxygen demand ([@b149-vhrm-4-1043]). This improves cardiac performance without altering RV contractility ([@b26-vhrm-4-1043]) and cardiac output in hemodynamically stable patients with a variety of causes of pulmonary hypertension ([@b33-vhrm-4-1043]; [@b13-vhrm-4-1043]). INO has a very short half-life and almost no systemic vasodilatory effects, which is very important in treatment of hemodynamically unstable patients. While underlying causes of RV failure and baseline hemodynamics did not predict response to INO, the use of alpha-agonist catecholamines did ([@b13-vhrm-4-1043]).

Multiple studies on utilization of the INO in ARDS patients showed improved oxygenation for 24--48 hours, variable improvement in mean PAP ([@b83-vhrm-4-1043]) and no significant impact on the duration of ventilatory support or mortality in this patient population ([@b59-vhrm-4-1043]; [@b128-vhrm-4-1043]). A combination of INO and other interventions, such as positive end-expiratory pressure and prone positioning, yielded beneficial and additive effects on arterial oxygenation ([@b59-vhrm-4-1043]). INO has been successfully used and associated with improved outcomes in critically ill postoperative patients, who developed severe pulmonary hypertension or RV failure ([@b28-vhrm-4-1043]; [@b40-vhrm-4-1043]).

A combination treatment of INO with other pulmonary vasodilators (milrinone, sildenafil etc) has been used in management of acute pulmonary hypertension in different conditions ([@b27-vhrm-4-1043]; [@b76-vhrm-4-1043]). INO treatment is associated with multiple side effects including methemoglobinemia ([@b109-vhrm-4-1043]; [@b134-vhrm-4-1043]) and NO~2~ formation ([@b134-vhrm-4-1043]). Abrupt withdrawal of NO has been associated with rebound pulmonary hypertension, significant drop in PaO~2~ and life-threatening hemodynamic deterioration ([@b134-vhrm-4-1043]; [@b25-vhrm-4-1043]). Close monitoring and gradual discontinuation is important to prevent and detect rebound pulmonary hypertension.

### Prostaglandins

Prostaglandin E~1~ and prostacyclin both produce significant pulmonary vasodilatation and can lower PVR. Both possess antithrombotic, antiproliferative and anti-inflammatory properties. In patients with chronic severe pulmonary hypertension, intravenous prostacyclin is highly effective and associated with a significant survival benefit ([@b84-vhrm-4-1043], [@b85-vhrm-4-1043]). Prostacyclin, subcutaneous or intravenous treprostinil, intravenous PGE~1~ and other prostanoids have relatively long half-lives and can significantly affect systemic hemodynamics. This feature limits their use in critically ill or hemodynamically unstable patients. Intravenous prostacyclin (PGI~2~) in combination with norepinephrine and dopamine was effective in the treatment of protamine-mediated acute pulmonary hypertension and RV failure in the setting of open heart surgery ([@b107-vhrm-4-1043]).

Prostacyclin and its analogs (iloprost and treprostinil) in inhaled forms are as effective as intravenous forms in patients with chronic pulmonary hypertension ([@b43-vhrm-4-1043]). In the ICU setting inhaled prosaglandins have been used to treat severe sustained pulmonary hypertension and intractable hypoxia, but were associated with systemic hypotension ([@b44-vhrm-4-1043]). Inhaled iloprost effectively decreased pulmonary artery pressure and improved RV performance immediately after separation from cardiopulmonary bypass ([@b129-vhrm-4-1043]). Inhaled iloprost was effective in the treatment of acute RV dysfunction in the setting of pre-existing pulmonary hypertension in heart transplant recipients during weaning from cardiopulmonary bypass circulation and was not associated with significant systemic side-effects.

Despite the observation that RV ejection fraction increased on INO, but not with PGI~2~, both INO and PGI~2~-aerosol showed beneficial effects on RV performance and may prove helpful in the treatment of acute pulmonary hypertension ([@b149-vhrm-4-1043]). Inhaled prostacyclin showed different effect on oxygenation and pulmonary hemodynamics in patients presenting with primary pulmonary ARDS (reduction in PaO~2~/FIO~2~) compared with extrapulmonary cause of ARDS (increase in PaO~2~/FIO~2~ along with a decrease in mean PAP) ([@b29-vhrm-4-1043]).

### Milrinone

Milrinone is a selective phosphodiesterase-3 inhibitor with significant inotropic and vasodilatory effects for both pulmonary and systemic vasculatures. It is widely used alone or in combinations in patients with decompensated heart failure, particularly in those with nonischemic left ventricular systolic dysfunction ([@b89-vhrm-4-1043]; [@b32-vhrm-4-1043]) and cardiac surgery patients ([@b79-vhrm-4-1043]; [@b74-vhrm-4-1043]). In animal models of both acute and chronic pulmonary hypertension, milrinone significantly reduced PVR and improved RV function ([@b23-vhrm-4-1043]; [@b45-vhrm-4-1043]). In cardiac surgery patients with a history of pulmonary hypertension, INO was associated with lower heart rates, higher right ventricular ejection fraction, and a lower requirement for treatment with vasopressor agents compared to milrinone ([@b121-vhrm-4-1043]).

The systemic vasodilatory effect of milrinone along with relatively long half life is the major limiting factors against its utilization in conditions associated with systemic hypotension or hemodynamic instability. However, in combination with INO, milrinone produced additive pulmonary vasodi-latation in animal model of acute pulmonary hypertension ([@b27-vhrm-4-1043]). A combination of milrinone and sildenafil led to more effective pulmonary vasodilation and increased RV contractility, without additional systemic vasodilatation in an animal model. CO and RV performance were sig-nificantly improved after milrinone or both drugs combined, but not with sildenafil alone ([@b80-vhrm-4-1043]). Systemic vasopressors, both norepinephrine and low dose vasopressin were effective in the treatment of milrinone-induced systemic hypotension. However, milrinone-vasopressin combination was associated with better hemodynamics than milrinone-norepinephrine during the management of right heart failure ([@b57-vhrm-4-1043]). In a volume-resuscitated pediatric patient with septic shock, when administered in addition to catecholamines, milrinone improved cardiovascular function ([@b10-vhrm-4-1043]).

In an animal model of drug-induced pulmonary hypertension nebulization of milrinone failed to deliver sufficient amount of milrinone for producing a detectable hemodynamic effect ([@b39-vhrm-4-1043]), but in animals with induced CHF inhalation of milrinone predominantly dilated pulmonary blood vessels, resulting in a reduced pulmonary-to-systemic vascular resistance ratio and improvement of pulmonary venous hypertension ([@b46-vhrm-4-1043]). At the same time, in animals after cardiopulmonary bypass inhaled milrinone produced adequate hemodynamic and oxygenation profiles, and prevented the occurrence of the pulmonary endothelial dysfunction. ([@b70-vhrm-4-1043]).

### Sildenafil and other phosphodiesterase-5 inhibitors

Sildenafil is a specific phosphodiesterase-5 inhibitor with sustained pulmonary vasodilatatory effect. Sildenafil lowers PVR, PAP, and increases CO in patients with different forms of chronic pulmonary hypertension ([@b92-vhrm-4-1043]; [@b93-vhrm-4-1043]) including patients with pulmonary hypertension secondary to congestive heart failure ([@b77-vhrm-4-1043]). This effect is mainly achieved by balancing pulmonary and systemic vasodilation. In patients after coronary artery bypass graft surgery sildenafil may improve myocardial perfusion, reduce platelet activation, and potentially reduce early graft occlusion ([@b37-vhrm-4-1043]). In the chronic setting it is highly effective both alone and in combination with other pulmonary vasodilators: epoprostenol ([@b122-vhrm-4-1043]), iloprost ([@b41-vhrm-4-1043], [@b42-vhrm-4-1043]), brain natriuretic peptide (BNP) ([@b66-vhrm-4-1043]), and inhaled NO ([@b77-vhrm-4-1043]). Although mostly used in patients with chronic pulmonary hypertension and in hemodynamically stable patients sildenafil possesses multiple features that could be effective in treatment of critically ill patients with severe RV dysfunction related to secondary pulmonary hypertension ([@b106-vhrm-4-1043]). Its ability to augment and prolong the hemodynamic effects of other pulmonary vasodilators has been successfully used to minimize rebound pulmonary hypertension after INO discontinuation ([@b4-vhrm-4-1043]; [@b131-vhrm-4-1043]; [@b102-vhrm-4-1043]), weaning from intravenous vasodilators in patients after cardiac surgery ([@b131-vhrm-4-1043]) as well as in chronic PAH therapy ([@b58-vhrm-4-1043]).

Experimental evaluation of the inhaled and intravenous sildenafil administration showed similar effects on pulmonary endothelium-dependent relaxation, overall hemody-namic profile and oxygenation after cardiopulmonary bypass. Both administration routes prevented a significant increase in mean PAP without severe systemic hypotension ([@b6-vhrm-4-1043]).

Two other specific phosphodiesterase-5 inhibitors: zapri-nars and dipyridamole seem to be potentially very effective in the management of acute pulmonary hypertension. Administration of either of these drugs leads to dose-dependent pulmonary vasodilation and no significant systemic arterial hypotension ([@b81-vhrm-4-1043]). Intravenous zaprinast may increase the efficacy and prolong the duration of action of INO. However, its efficacy in lung injury models was uncertain: nonselective vasodilation induced by intravenously administered zaprinast not only worsens gas exchange, but also abolishes the beneficial effects of INO ([@b1-vhrm-4-1043]). Subthreshold doses (which do not reduce PAP) of specific phosphodiesterase-5 inhibitors (zaprinast and sildenafil) when used in acute lung injury (ALI) associated with pulmonary hypertension improved responsiveness to NO ([@b64-vhrm-4-1043]). Dipyridamole effectively slows the progression of hypoxemic pulmonary hypertension in patients with COPD ([@b104-vhrm-4-1043]). In an animal model of acute pulmonary hypertension, IV dipyridamole in combination with INO decreased pulmonary artery pressure for a prolonged period of time and reduced exposure to NO ([@b35-vhrm-4-1043]). Dipyridamole can lower PVR, augment INO-induced pulmonary vasodilation, acutely attenuate the adverse hemodynamic effects of rapid withdrawal of INO therapy ([@b53-vhrm-4-1043]), and attenuate excessive hypoxic pulmonary vasoreactivity ([@b148-vhrm-4-1043]). In pediatric patients with pulmonary hypertension dipyridamole decreased PVR index to similar values as INO did, but with significant systemic vasodilata-tion ([@b148-vhrm-4-1043]). Intravenous dipyridamole has been used to identify reversibility of pulmonary hypertension in potential cardiac transplant recipients with CHF in whom a pulmonary vasodilator response to inhalation of NO alone is not observed ([@b76-vhrm-4-1043]). Intravenous dipyri-damole was also used in acute management of pulmonary hypertension in combination either with INO or intravenous nitroglycerin ([@b126-vhrm-4-1043]).

### Natriuretic peptides

Natriuretic peptides (atrial natriuretic peptide \[ANP\] and brain natriuretic peptide \[BNP\]) in addition to their diuretic, vasorelaxing, and hemodynamic effects are able to inhibit vascular smooth-muscle proliferation and cardiac hypertrophy, as well as counteract the renin--angiotensin system ([@b67-vhrm-4-1043]). ANP and BNP produced dose-related pulmonary vasodilatation in patients with cor pulmonale, without worsening oxygen saturation or affecting systemic hemodynamics and exerted favorable neurohormonal effects by suppressing aldosterone ([@b20-vhrm-4-1043]). Although both ANP and BNP exhibit pulmonary vasorelax-ing activity, only BNP significantly attenuated the mean PAP and acute hypoxic pulmonary vasoconstriction in otherwise healthy individuals ([@b19-vhrm-4-1043]). BNP alone had no effect on mean PAP or PVR in patients with PAH, but was well tolerated and augmented the acute pulmonary vasodilator effect of sildenafil ([@b66-vhrm-4-1043]). Nesiritide acutely and significantly reduced PA pressure, PVR, and biventricular filling pressures in patients with postcapil-lary pulmonary hypertension. However, in patients with precapillary pulmonary hypertension, it had no significant acute hemodynamic effect on the pulmonary hemodynamics ([@b91-vhrm-4-1043]). Use of nesiritide in hemodynamically unstable and hypotensive patients is limited, mainly because of reduction of systemic vascular resistance and resulting profound systemic hypotension ([@b144-vhrm-4-1043]).

### Other pulmonary vasodilators

Nitroprusside and nitroglycerin both can cause significant pulmonary vasodilation similar to that of INO. However, nitroprusside has a longer half life and can cause acute reduction of systemic vascular resistance leading to systemic hypotension associated with a decrease in RV contractility, limiting its use in hemodynamically unstable and hypotensive patients ([@b26-vhrm-4-1043]). A significant venodilator effect of nitroglycerine decreases RV preload leading to adverse consequences in patients with right heart failure. Inhaled nitroglycerin may be a safer therapeutic option leading to a significant reduction in both mean PAP and PVR in patients after mitral valve operations without reducing systemic mean arterial pressure ([@b146-vhrm-4-1043]).

Intravenous adenosine is a pulmonary vasodilator with a very short half-life (6--10 sec.) and can be effective for short term lowering PVR ([@b84-vhrm-4-1043]). In the setting of acute pulmonary hypertension adenosine infusion may help lower PAP without lowering systemic arterial pressure and reverse the clinical state of shock by achieving pulmonary vasodilatation ([@b36-vhrm-4-1043]). However, higher doses (70 mg/kg per min to 100 mg/kg per min) cause systemic vasodilation ([@b123-vhrm-4-1043]). Adenosine is used to treat persistent pulmonary hypertension of the newborn ([@b105-vhrm-4-1043]; [@b100-vhrm-4-1043]).

Calcium channel blockers have been used in hemodynam-ically stable patients with PAH who demonstrated pulmonary vascular response to acute vasodilator challenge ([@b7-vhrm-4-1043]). There are no studies of calcium channel blockers in critically ill patients with acute pulmonary hypertension. Acute administration of nifedipine did not cause pulmonary vasodilation, and in contrast led to increased RVEDP and decreased RV contractility ([@b26-vhrm-4-1043]). Prolonged half-life and negative inotropic effects, which may precipitate fatal worsening of RV failure, limit the use of calcium channel blockers in treatment of acute pulmonary hypertension.

Endothelin receptor antagonists appear to be highly effective in treatment PAH in outpatient settings ([@b7-vhrm-4-1043]). They have not been studied in acute care settings. In an animal model pre-treatment with bosentan completely abolished endotoxin-induced acute pulmonary hypertension and changes in pulmonary compliance and resistance ([@b2-vhrm-4-1043]). Currently the only possible implication in critically ill patients would be weaning or conversion from inhaled or intravenous pulmonary vasodilators to oral medication (bosentan) ([@b58-vhrm-4-1043]).

Vasopressors and inotropic agents
---------------------------------

Critically ill patients with associated acute pulmonary hypertension frequently develop profound and refractory systemic arterial hypotension. In cases with severe acute arterial pulmonary hypertension (eg, massive PE) relieving the acute obstruction (either mechanically or with pulmonary vasodilators) of the pulmonary circulation can successfully resolve systemic arterial hypotension. In acute pulmonary hypertension associated with decreased cardiac contractility and/or systemic vascular resistance (SVR) the use of vasopressors with or without pulmonary vasodilators is necessary to maintain coronary and end organ perfusion. Progression of RV failure should be always considered in the management plan. Cases of severe acute pulmonary hypertension combined with heart failure and systemic arterial hypotension require tight hemodynamic monitoring and aggressive treatment with combinations of pulmonary vasodilators, inotropic agents and systemic arterial vaso-constrictors. The choice of vasopressor and inotropes in patients with acute pulmonary hypertension should take into consideration their effects on PVR and cardiac output when used alone or in combinations with other agents, and must be individualized based on individual patient response. Most traditional vasopressors and inotropes have not been studied in the setting of severe acute arterial pulmonary hypertension and hemodynamic instability.

Dobutamine is the most studied inotropic agent in patients with pulmonary hypertension. Administration of dobutamine augments myocardial contractility and reduces left ventricular afterload. It can cause systemic hypotension in some patients because of peripheral vasodilatory effects, which may require use of norepinephrine or other peripheral vasoconstrictors to maintain appropriate systemic perfusion pressures. In low doses (up to 5 μg/kg/min) dobutamine decreased PVR, lowered MAP and slightly increased cardiac output ([@b16-vhrm-4-1043]); at doses of 5--10 μg/kg per min, dobutamine caused significant tachycardia and systemic hypotension without improving PVR ([@b16-vhrm-4-1043]; [@b63-vhrm-4-1043]). In combination with INO dobutamine administration had additive effects on pulmonary circulation ([@b16-vhrm-4-1043]), increased cardiac performance and improved oxygenation (P/F patio) ([@b140-vhrm-4-1043]) with no effect on systemic hemodynamics. In an animal model of acute RV failure secondary to acute pulmonary hypertension, dobutamine was superior to norepinephrine in improving RV function by optimizing pulmonary vasodilation, decreasing PA resistance and elastance and increasing RV contractility ([@b63-vhrm-4-1043]).

Norepinephrine has significant inotropic effects and produces vasoconstriction. It is widely used in critical care settings to treat hemodynamically unstable patients. In addition to positive effects on cardiac output and systemic arterial pressure, norepinephrine increases PVR and worsens pulmonary artery hypertension ([@b68-vhrm-4-1043]). However, norepeinephrine is superior to phenylephrine in restoring systemic arterial pressure, decreasing PVR, augmenting right ventricular myocardial blood flow and improving cardiac output in animal model of acute PE ([@b48-vhrm-4-1043]). Alfa-adrenergic stimulation can cause a disproportionate rise in PVR ([@b17-vhrm-4-1043]) which is implicated in the development of acute pulmonary hypertension in critical illnesses. Besides disproportional a increase in PVR phenylephrine also causes bradycardia ([@b130-vhrm-4-1043]) with detrimental consequences on pulmonary and systemic hemodynamic.

The effects of phenylephrine and norepinephrine in the treatment of systemic hypotension were evaluated in patients with chronic pulmonary hypertension who developed systemic hypotension following induction of anesthesia. In contrast to phenylephrine norepinephrine decreased the ratio of pulmonary arterial pressure to systemic blood pressure without a change in cardiac index. Thus, norepinephrine has been considered to be preferable to phenylephrine for the treatment of hypotension in patients with chronic pulmonary hypertension ([@b68-vhrm-4-1043]). There is growing data (as we have partially presented earlier) on successful combination of norepinephrine and selective pulmonary vasodilators in the treatment of patients with acute and chronic pulmonary hypertension ([@b133-vhrm-4-1043]).

Dopamine produces dose dependent dopaminergic, beta- and alpha-adrenergic effects on cardiac output and vascular tone. In patients with chronic pulmonary hypertension dopa-mine infusion led to increased heart rate, mean PAP, aortic mean pressure, and cardiac index with concomitant fall of systemic vascular resistance ([@b51-vhrm-4-1043]). Administration of dopamine, similar to epinephrine, is associated with high risk of tachyarrhythmia, with potentially fatal consequences in patients with severe pulmonary hypertension ([@b130-vhrm-4-1043]). In a small animal study of sepsis-induced pulmonary hypertension epinephrine infusion increased SVR and cardiac output and lowered PVR ([@b88-vhrm-4-1043]). There is no other supportive data on use epinephrine in patients with chronic or acute pulmonary hypertension.

Isoproterenol has positive inotropic and chronotropic effect, which in therapeutic doses increases cardiac output and produces pulmonary and peripheral vasodilation. As a pulmonary vasodilator, isoproterenol is one of the preferred inotropic agents in heart transplantation patients with elevated PVR. The dosage of isoproterenol should be reduced gradually because PVR may return quickly to elevated baseline levels after discontinuation of this drug ([@b123-vhrm-4-1043]). In animals with acute pulmonary hypertension administration of isoproterenol did not reduce PAP, and instead produced significant tachycardia and was associated with arrhythmias ([@b110-vhrm-4-1043]).

Vasopressin is an endogenous hormone with weak non-adrenergic vasopressor effect on the systemic vasculature and an ability to produce NO mediated selective pulmonary vasodilation ([@b31-vhrm-4-1043]). In healthy animals a linear relationship was observed between vasopressin levels and systemic vascular resistance. However, vasopressin did not affect PVR or any vascular compliance ([@b141-vhrm-4-1043]). It was very effective (at dose of 0.1 U/min) in treating refractory low SVR hypotension concomitant with pulmonary hypertension in postoperative patients ([@b127-vhrm-4-1043]). Experimental data on use of vasopressin in acute pulmonary hypertension is controversial: In one setting of acute pulmonary vasoconstriction vasopressin infusion produced signifi-cant pulmonary vasodilation ([@b132-vhrm-4-1043]). Use of high dose of vasopressin (1.16 units/kg/h ) in another animal model of acute pulmonary hypertension led to increased PVR and decreased cardiac output with a decrease in RV contractility, leading the authors to cautioning against its use when RV function is compromised ([@b73-vhrm-4-1043]) .

Experimental data suggest that levosimendan (a myocar-dial and vascular calcium sensitizer) has pulmonary vaso-dilatory properties which, in combination with its positive inotropic effects, would render it particularly attractive for the treatment of RV dysfunction related to acute pulmonary hypertension. In a model of acute right ventricular dysfunction, levosimendan improved global hemodynamics and optimized right ventriculo-vascular coupling via a moderate increase in RV contractility and a mild reduction of RV afterload ([@b96-vhrm-4-1043]). A similar effect was achieved in an animal model of progressive pulmonary hypertension and RV failure related to recurrent pulmonary embolism ([@b62-vhrm-4-1043]). In those settings levosimendan restored RV function better than dobutamine because of similar inotropic effects and additional pulmonary vasodilatory effects ([@b63-vhrm-4-1043]) Levosimendan was successfully combined with milrinone in one study ([@b124-vhrm-4-1043]). A pilot prospective, randomized study on patients with ARDS in association with septic shock showed that levosimendan improves right ventricular performance mainly through pulmonary vasodilator effects ([@b99-vhrm-4-1043]).

Fluid management
----------------

Experiments in 1983 showed that when RV afterload is increased, even a relatively small increase in preload may result in RV dysfunction. RV dysfunction occurred with volume expansion, despite constant PVR and a decrease in mean PAP. This and further observations draw the conclusion that high RV filling pressure restores normal hemodynamics only if PVR is normal and RV contractility is not markedly reduced ([@b135-vhrm-4-1043]).

In patients with pulmonary hypertension, RV dysfunction/failure can reduce LV filling and lead to cardiogenic shock. Patients with cardiogenic shock secondary to RV dysfunction usually have a very high (\>20 mm Hg) RV filling pressure ([@b54-vhrm-4-1043]). In addition to decreased RV contractility and cardiac output RV dilatation can further limit LV filling via ventricular interdependence, which causes shifting of the interventricular septum toward the LV cavity. Following the traditional paradigm that RV failure is treated with aggressive fluid resuscitation can, thus, worsen the patient's condition. The challenge in fluid management in those patients is to find the optimal RV preload necessary to avoid the detrimental effects of ventricular interdependence on LV function. Hemodynamic monitoring of patients with RV failure due to acute RV myocardial infarction showed that cardiac and stroke indexes increased and the RV reached its maximum stroke work index when the filling pressure was 10--14 mm Hg. These values may be regarded as the optimal level of RV filling pressure in patients with RV infarction ([@b11-vhrm-4-1043]). There is no data on optimal RV filling pressure in patients with RV dysfunction secondary to acute pulmonary hypertension.

Ventilator management
---------------------

It was found that controlled ventilation altered RV function primarily by increasing RV afterload during the lung inflation period ([@b55-vhrm-4-1043]). Transpulmonary pressure (and related tidal volume), but not airway pressure itself, was the main determinant factor of RV afterload during mechanical ventilation ([@b136-vhrm-4-1043]). This supports a low-volume strategy in ARDS, recommended as a protective measure for lung parenchyma, which might also represent a protective measure for the RV and pulmonary circulation ([@b136-vhrm-4-1043]). Frequency of acute cor pulmonale in ARDS patients declined from 61% to 25% over the last 15--30 years, which could be explained in part by fundamental alterations in respiratory support and implementation low tidal volume ventilation ([@b139-vhrm-4-1043]). Lower incidence of acute cor pulmonale in ARDS patients was associated with lower (less then 27--30 mmHg) plateau pressure ([@b56-vhrm-4-1043]).

RV systolic function was generally negatively affected by end-expiratory pressure (PEEP) in ARDS patients undergoing mechanical ventilation. In those patients PEEP titration significantly affected RV outflow impedance, the lowest values of which was associated with the achieved better total quasi-static lung compliance (calculated by dividing tidal volume by the difference between plateau and end-expiratory airway pressures) ([@b117-vhrm-4-1043]). This suggests that lung hyperinflation along with either inadequate or excessive PEEP can significantly reduce RV systolic function and cardiac output. On other hand, in an experimental study on healthy animals, the open lung concept ventilation resulted in significantly improved lung aeration with no negative effect on RV afterload or LV afterload. This is possibly explained by a loss of hypoxic pulmonary vasoconstriction due to alveolar recruitment. The reductions in the CO and in the mean PAP were the consequences of a reduced preload ([@b95-vhrm-4-1043]). A clinical study in patients after cardiac surgery found no evidence that ventilation according to the open lung concept affects RV afterload ([@b112-vhrm-4-1043]).

Hypercapnia has been shown to induce pulmonary hypertension in animal models. There is no data on how it could affect acute pulmonary hypertension in humans. However, study on healthy volunteers revealed that human pulmonary vascular responses to hypercapnia and hypocapnia consist, respectively, of constriction and dilatation that take 1.5--2 h to reach a steady level. The time courses for recovery in eucap-nia are similar. Hypercapnia generated a rise in cardiac output by changing heart rate; hypocapnia produced a fall in cardiac output by changing stroke volume. The finding of marked vasodilatation in response to hypocapnia demonstrates that there is normally a substantial vascular tone in the human pulmonary circulation ([@b8-vhrm-4-1043]).

Treatment with 100% oxygen is a selective pulmonary vasodilator in patients with sustained pulmonary hypertension, regardless of primary diagnosis, baseline oxygenation, or right ventricular function ([@b114-vhrm-4-1043]). In patients with ALI vascular response to oxygen was different and administration of 100% O~2~ worsened intrapulmonary shunt possibly secondary to collapse of unstable alveolar units with very low ventilation-perfusion (V A/Q) ratios. This is in contrast to administration of 100% O~2~ to patients with COPD, in whom only the dispersion of the blood flow distribution was changed, suggesting release of hypoxic pulmonary vasoconstriction ([@b116-vhrm-4-1043]). Optimal supplemental oxygen management is an integral component of pulmonary hypertension therapy in the ICU ([@b147-vhrm-4-1043]).

Other treatment options
-----------------------

The observations of a survival advantage in patients with pulmonary hypertension and a patent foramen ovale suggested that an intra-atrial right-to-left shunt could decompress the RV and increase LV pre-load, thereby increasing systemic blood flow and improving systemic oxygen transport despite arterial oxygen desaturation. Atrial septostomy has been developed as an alternative/bridge treatment and applied in patients with lack of response to medical therapy in the absence of other surgical treatment options. It has a substantial morbidity and mortality in critically ill patients with severe RV failure ([@b115-vhrm-4-1043]). With growing experience, procedure-related death rates have been reduced to 5.4%, and the most suitable patient group has been identified among patients with a mean right atrial pressure between 10 and 20 mm Hg ([@b65-vhrm-4-1043]). Acute right heart failure after orthotopic heart transplantation was successfully managed by decompression of the RV through the patent foramen ovale of the donor heart and inhalation of iloprost ([@b108-vhrm-4-1043]). Both pericardiectomy and creation of atrial septal defects have been used in extreme cases of acute RV failure secondary to acute MI ([@b113-vhrm-4-1043]). Decompression of the RV through the septostomy may potentially be an effective alternative in the management of severe acute pulmonary hypertension in ICU setting. The defect could be subsequently closed using a transcatheter septal occlusion device, after the patient's condition has been stabilized.

In cases of acute right heart failure after heart transplantation, mechanical circulatory support systems, such as RV assist devices, extracorporeal membrane oxygenation, femoral vein-to-femoral artery roller or centrifugal pumps, may facilitate hemodynamic stability until the transplanted heart has recovered, or until a new heart has been found for retransplantation ([@b5-vhrm-4-1043]). They possibly could be successfully applied in other cases of potentially reversible acute pulmonary hypertension and cor pulmonale. Intra-aortic balloon counterpulsation (IABP) has long been the mainstay of mechanical therapy for cardiogenic shock. Not every patient has a hemodynamic response to IABP ([@b113-vhrm-4-1043]). However, in patients with acute pulmonary hypertension and RV failure associated with systemic hypotension it could improve coronary and peripheral perfusion and augment LV performance with an acute decrease in afterload ([@b3-vhrm-4-1043]).

Conclusion
==========

Many complex medical disorders managed in noncardiac ICUs are associated with an elevation of PAP. In some circumstances serious and prolonged elevation of PAP progresses to severe acute pulmonary hypertension, leading to life threatening complications including refractory systemic arterial hypotension, severe hypoxemia, RV dysfunction and failure and ultimately resulting in cardiogenic and/or obstructive shock and death. Unfortunately, in most cases acute pulmonary hypertension remains under diagnosed and its treatment begins only after serious complications have developed.

Significant pathophysiologic differences between acute and chronic pulmonary hypertension made current treatment recommendations for chronic pulmonary hypertension dif-ficult to apply to acute pulmonary hypertension. Based on available data, therapy of acute arterial pulmonary hypertension should be generally aimed at acutely relieving RV pressure overload by decreasing PVR and preventing or reversing RV dysfunction with pulmonary vasodilators and inotropes. Cases of severe acute pulmonary hypertension combined with developing heart failure and systemic arterial hypotension are real clinical challenges requiring tight hemodynamic monitoring and aggressive treatment including combinations of pulmonary vasodilators, inotropic agents and systemic arterial vasoconstrictors (see [Figure 1](#f1-vhrm-4-1043){ref-type="fig"}). The choice of vasopressor and inotropes in patients with acute pulmonary hypertension should take in consideration their effects on PVR and cardiac output when used alone or in combinations with other agents, and must be individualized based on individual patient response.

Our review revealed significant gaps in basic science knowledge, clinical studies and management recommendations for acute arterial pulmonary hypertension in the critically ill. Intensivists need to be aware of acute pulmonary hypertension in critical conditions, the importance of its early recognition and appropriate treatment.
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###### 

Clinical classification of pulmonary hypertension -- Venice 2003

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **1. Pulmonary arterial hypertension (PAH)**
    1.1. Idiopathic (IPAH)
    1.2. Familial (FPAH)
    1.3. Associated with (APAH):
    1.3.1. Connective tissue disease
    1.3.2. Congenital systemic to pulmonary shunts
    1.3.3. Portal hypertension
    1.3.4. HIV infection
    1.3.5. Drugs and toxins
    1.3.6. Other (thyroid disorders, glycogen storage disease, Gaucher's disease, hereditary hemorrhagic telangiectasia, hemoglobinopathies, myeloproliferative disorders, splenectomy)
    1.4. Associated with significant venous or capillary involvement
    1.4.1. Pulmonary veno-occlusive disease (PVOD)
    1.4.2. Pulmonary capillary hemangiomatosis (PCH)
    1.5. Persistent pulmonary hypertension of the newborn (PPHN)
  **2. Pulmonary hypertension associated with left heart diseases**
    2.1. Left-sided atrial or ventricular heart disease
    2.2. Left-sided valvular heart disease
  **3. Pulmonary hypertension associated with lung respiratory diseases and/or hypoxia**
    3.1. Chronic obstructive pulmonary disease
    3.2. Interstitial lung disease
    3.3. Sleep disordered breathing
    3.4. Alveolar hypoventilation disorders
    3.5. Chronic exposure to high altitudes
    3.6. Developmental abnormalities
  **4. Pulmonary hypertension due to chronic thrombotic and/or embolic disease**
    4.1. Thromboembolic obstruction of proximal pulmonary arteries
    4.2. Thromboembolic obstruction of distal pulmonary arteries
    4.3. Nonthrombotic pulmonary embolism (tumor, parasites, foreign material)
  **5. Miscellaneous** (Sarcoidosis, histiocytosis X, lymphangiomatosis, compression of pulmonary vessels (adenopathy, tumor, fibrosing mediastinitis)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Pulmonary hypertension in the intensive care unit

  ----------------------------------------------------------------------------------------------------------------------
  • **Acute and acute-on-chronic venous pulmonary hypertension**
  Pulmonary hypertension secondary to left ventricular dysfunction/failure with left atrial hypertension
    -- CHF, acute MI, diastolic dysfunction, severe valvular disease (MR, MS, etc)
    -- Pulmonary venoocclusive disease (VOD)
  • **Acute-on-chronic arterial pulmonary hypertension**
  Worsening of preexisting pulmonary hypertension, usually with respiratory or cardiovascular decompensation either as
    -- Natural progression or
    -- Precipitated by acute condition (such as sepsis/ARDS, PE, drugs etc)
  • **Acute arterial pulmonary hypertension**
  Without preexisting pulmonary hypertension
    -- Massive PE
    -- ARDS, sepsis, drug-induced, etc.
  ----------------------------------------------------------------------------------------------------------------------

**Abbreviations:** ARDS, acute respiratory distress syndrome; CHF, chronic heart failure; MI, myocardial infection; MR, mitral regurgitation; MS, mitral stenosis; PE, pulmonary embolism; VOD, pulmonary veno-occlusive disease.

###### 

Factors predisposing to adverse outcome in patients with preexisting pulmonary hypertension

  --------------------------------------------------------------------------------
  • **Pulmonary:**
    -- Chronic hypoxia, predisposition to hypoxic respiratory failure;
    -- Restrictive lung disease (with or w/o COPD);
    -- Decreased DLCO;
    -- Decreased pulmonary compensatory capacity.
  • **Cardiovascular:**
    -- Pulmonary arterial hypertension (with or w/o venous component);
    -- Increased right to left shunting;
    -- Right ventricular strain, predisposition to right ventricular failure;
    -- Systemic use of vasoactive agents;
    -- RV hyperthrophy, requiring higher RV preload
    -- Decreased compensatory capacity.
  • **Response to infection:**
    -- Use of immunosuppressive, disease modifying drugs for underlying disease;
    -- Malnutrition and overall decreased functional reserve
  • **Visceral congestion:**
    -- As a result of RV failure. Predisposes to multiorgan failure.
  --------------------------------------------------------------------------------

**Abbreviations:** COPD, chronic obstructive pulmonary disease; DLCO, diffusing capacity of the lung for carbon monoxide; RV, right ventricle.
